#paxlovid

[ follow ]
covid-19
The Mercury News
2 months ago
Health

Why COVID patients who could most benefit from Paxlovid still aren't getting it

Paxlovid's high cost is a barrier to access for many patients.
Awareness of Paxlovid's benefits and free access programs is low. [ more ]
Los Angeles Times
3 months ago
Health

'If it's COVID, Paxlovid'? For many, it should be easier to get. Here's what to know about antivirals

Access to Paxlovid, the COVID-19 therapeutic, is hindered by doctors' reluctance to prescribe it
Doctors' concerns about 'Paxlovid rebound' are unfounded as COVID-19 rebound can happen with or without the drug [ more ]
www.nytimes.com
4 months ago
Health

I Have Covid. Should I Take Paxlovid?

Paxlovid can prevent severe illness in high-risk individuals
Many people may not be aware they qualify for Paxlovid or may be hesitant to take it [ more ]
morecovid-19
www.scientificamerican.com
1 month ago
Coronavirus

Paxlovid COVID Treatment Most Beneficial for Unvaccinated People with Risk Factors. Others May Not Need It

Paxlovid was widely used for COVID treatment but may not be as effective in all cases, particularly for those at low or moderate risk of severe infection. [ more ]
ABC7 San Francisco
4 months ago
Coronavirus

Paxlovid does not lower risk of long-term COVID-19 symptoms, UCSF study shows

Patients who took Paxlovid had similar outcomes to those who did not in terms of long COVID symptoms. [ more ]
www.bostonherald.com
2 months ago
Health

Why COVID patients who could most benefit from Paxlovid still aren't getting it

The high cost of Paxlovid is a barrier to access for many patients.
Low awareness among patients and doctors about Paxlovid's benefits and application process. [ more ]
time.com
4 months ago
Health

I'm Young and Healthy. Should I Take Paxlovid?

Paxlovid, an antiviral drug, is beneficial for high-risk individuals in preventing severe COVID-19 outcomes.
Studies suggest that young and healthy individuals without risk factors for severe COVID-19 are unlikely to benefit from taking Paxlovid. [ more ]
time.com
6 months ago
Health

Rebound Infections Occur in 20% of Paxlovid Users, According to New Research

Around 20% of people taking nirmatrelvir-ritonavir (Paxlovid) for COVID-19 could experience rebound infections.
Patients experiencing rebound infections may still have live virus and can spread it to others.
Previous studies reported lower rebound rates, but a new study specifically investigates the rebound effect. [ more ]
Axios
3 months ago
Medicine

Exclusive: Biden admin officials push pharmacy execs on Paxlovid costs

The Biden administration is urging pharmacy chains to provide accurate information about the cost of the COVID-19 treatment Paxlovid.
Patients have sometimes been charged the full list price of $1,400 for Paxlovid, leading to low uptake of the medication. [ more ]
MedCity News
3 months ago
Law

Ex-Pfizer Employee Convicted for Insider Trades Ahead of Positive Paxlovid Data

A former Pfizer employee has been convicted of insider trading after buying options in the company's stock prior to the announcement of positive Covid-19 drug data.
The employee, Amit Dagar, was a senior statistical program lead for the clinical trial of Pfizer's drug Paxlovid, which showed an 89% reduction in hospitalization or death compared to a placebo. [ more ]
www.nytimes.com
4 months ago
Public health

Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.

Low uptake of the effective Covid-19 treatment drug, Paxlovid, has raised concerns among medical researchers.
Doctors' concerns about drug interactions and patients' worries about side effects may contribute to the low usage of Paxlovid. [ more ]
[ Load more ]